Lundbeck Inc. (formerly Ovation Pharmaceuticals) is staying on the look-out for niche pharmaceuticals that larger drugmakers cast aside. The company's focus is on marketing and developing drugs for central nervous system (CNS) disorders, as well as cancer drugs and hospital-based therapies for rare conditions. Its FDA-approved products for neurological conditions include treatments for ADHD, anxiety, and seizures. The company's pipeline includes several CNS products including epilepsy drugs, drug addiction therapies, and seizure medications. Among its other marketed products are several oncology drugs, as well as a treatment for lead poisoning. The company was acquired by Denmark-based H. Lundbeck in 2009.